A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Solid TumorSEQ Expanded Panel : 1017066
Test CodeMDFCPSTEP or 1017066
CPT Codes
0379U
Includes
see below link to gene chart
https://s7d6.scene7.com/is/image/questdiagnostics/FAQ273_Q4_Table_Gene_Content-1
https://s7d6.scene7.com/is/image/questdiagnostics/FAQ273_Q4_Table_Gene_Content-1
Transport Container
Submit Paraffin embedded tissue (PET) block accompanied by a circled H & E slide indicating the area to be examined: submit in sterile biohazard plastic bag.
Slides: submit 10 x 10 µm PET slides (minimum 5 x 5 µm) and H & E slide in slide holder.
Specimen to be tested must contain a minimum of 10 percent tumor (20 percent preferred).
Slides: submit 10 x 10 µm PET slides (minimum 5 x 5 µm) and H & E slide in slide holder.
Specimen to be tested must contain a minimum of 10 percent tumor (20 percent preferred).
Transport Temperature
Paraffin embedded Tissue Block: Ambient or on ice pack in summer; Slides: Ambient.
Specimen Stability
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Next Generation Sequencing
Setup Schedule
Monday & Wednesday & Friday
Report Available
10-14 days
Reference Range
An interpretive report will be provided.
Clinical Significance
The 523-gene expanded panel is intended to help oncologists deliver precision medicine by providing personalized genomic analysis of a patient’s tumor. The expanded panel offers the opportunity for a broader scope of genomic information. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials. This panel uses next-generation sequencing to detect mutations present in DNA and RNA extracted from formalin-fixed, paraffin embedded (FFPE) tissue sections of solid tumors. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also evaluated.
Performing Laboratory
med fusion